AL-ADTRAN
24.1.2023 16:13:34 CET | Business Wire | Press release
Adtran®, Inc., (NASDAQ:ADTN), the leading provider of next-generation open and disaggregated networking solutions, today launched its SDX 6330 10Gbit/s Combo PON fiber access platform, enabling service providers to rapidly and cost-effectively connect homes and businesses with fiber-based broadband. The new open and disaggregated solution offers the industry’s highest port density and is the first optical line terminal (OLT) with integrated 400Gbit/s uplinks. It will empower operators to accelerate fiber rollout and easily scale their networks to support dense urban, suburban and rural deployments. With enhanced energy efficiency, the highly compact, temperature-hardened fiber access platform will be important to meeting sustainability targets and addressing market demands for both retail and wholesale providers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230124005747/en/
Adtran’s SDX 6330 will help service providers meet subscriber demand in the most scalable and sustainable way possible. (Photo: Business Wire)
“Service providers face a tough environment as they strive to keep up with growing subscriber needs, expand coverage and meet green targets. With households and businesses accessing more and more data-hungry applications, operators need strategies in place to handle the surge in a cost-effective and sustainable way. This challenge is precisely what our third-generation fiber access platform aims to address,” said Robert Conger, SVP of technology and strategy at Adtran. “Our SDX 6330 offers the network simplicity, sustainability and scalability needed to power the Gigabit Society. That’s what makes it a compelling alternative to chassis-based architectures. It’s the solution many operators are searching for as they look to expand their market share while improving customer experience.”
The SDX 6330 is Adtran’s third generation of open and disaggregated OLT devices. With 48 ports of Combo PON in a compact and power-efficient design, it sets a new benchmark for lowering the total cost of deployment for 10Gbit/s services. Designed to deliver network simplicity and sustainability at scale, the solution offers deployment versatility and improved reach. Featuring open interfaces, it provides freedom to build best-in-class infrastructure with technology from multiple vendors, and its versatile architecture supports a wide range of network topologies and coherent optics. The SDX 6330 also helps meet corporate sustainability objectives by reducing power demand and landfill requirements.
“Our SDX 6330 is the most advanced fiber access platform in the industry, and the impact it’s about to have will be significant. By empowering service providers to reduce both the time and cost of getting people connected, we’re going to see broadband coverage increase like never before,” commented Ronan Kelly, CTO for EMEA and APAC at Adtran. “As pioneers in open and disaggregated fiber access innovation, we’ve consistently pushed boundaries, beginning with our industry-first deployments dating back to 2017. Now with our third-generation device, we’re taking density and scalability to new heights. Our SDX 6330 will transform networks into flexible, multigigabit service delivery platforms, empowering operators to stay ahead of the bandwidth consumption curve.”
About Adtran
Adtran, Inc. is a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. Adtran, Inc. is a wholly-owned subsidiary of ADTRAN Holdings, Inc. (NASDAQ:ADTN and FSE: QH9). Find more at Adtran, LinkedIn and Twitter.
Published by
Adtran, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005747/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
